Acne vulgaris: management

Supporting evidence

• Evidence review

• A: Information and support (PDF 767 KB)

  Published:

  25 June 2021

• B: Skin care advice for people with acne vulgaris (PDF 1.14 MB)

  Published:

  25 June 2021

• C: Dietary interventions for the treatment of acne vulgaris (PDF 1.08 MB)

  Published:

  25 June 2021

• D: Referral to specialist care (PDF 711 KB)

  Published:

  25 June 2021

• E1: Management options for mild to moderate acne – network meta-analyses (PDF 8.77 MB)

  Published:

  25 June 2021

• E2: Management options for mild to moderate acne – pairwise comparisons (PDF 3.16 MB)

  Published:

  25 June 2021

• F1: Management options for moderate to severe acne – network meta-analyses (PDF 6.71 MB)

  Published:

  25 June 2021

• F2: Management options for moderate to severe acne – pairwise comparisons (PDF 2.8 MB)

  Published:

  25 June 2021

• G: Management options for people with acne vulgaris and polycystic ovary syndrome (PDF 1.64 MB)

  Published:

  25 June 2021

• H: Management options for refractory acne (PDF 1.49 MB)

  Published:

  25 June 2021

• I: Maintenance treatment for acne vulgaris (PDF 2.18 MB)

  Published:

  25 June 2021

• J: Addition of oral corticosteroids to oral isotretinoin for the treatment of severe inflammatory acne vulgaris (PDF 552 KB)

  Published:

  25 June 2021

• K: Intralesional corticosteroids for the treatment of individual acne vulgaris lesions (PDF 502 KB)

  Published:

  25 June 2021

• L: Risk factors for scarring due to acne vulgaris (PDF 577 KB)

  Published:

  25 June 2021

• M: Management of acne vulgaris-associated scarring (PDF 2.97 MB)

  Published:

  25 June 2021

• Supplement 3 (evidence review E1, appendix M): TSU NMA software code (mild to moderate acne) (PDF 316 KB)

  Published:

  25 June 2021

• Supplement 4 (evidence review E1, appendix M): NMA data (mild to moderate acne) (Excel 152 KB)

  Published:

  25 June 2021

• Supplement 5 (evidence review E1, appendix M): NMA of efficacy – included and excluded studies (mild to moderate acne) (Excel 29 KB)

  Published:

  25 June 2021

• Supplement 6 (evidence review E1, appendix M): NMA, direct and indirect estimates (mild to moderate acne) (Excel 124 KB)

  Published:

  25 June 2021

• Supplement 7 (evidence review F1, appendix M): TSU NMA software code (moderate to severe acne) (PDF 312 KB)

  Published:

  25 June 2021

• Supplement 8 (evidence review F1, appendix M): NMA data (moderate to severe acne) (Excel 114 KB)

  Published:

  25 June 2021

• Supplement 9 (evidence review F1, appendix M): NMA of efficacy – included and excluded studies (moderate to severe acne) (Excel 26 KB)

  Published:

  25 June 2021

• Supplement 10 (evidence review F1, appendix M): NMA, direct and indirect estimates (moderate to severe acne) (Excel 62 KB)

  Published:

  25 June 2021

• Evidence reviews - June 2021

• Supplement 1: Methods (PDF 584 KB)

  Published:

  25 June 2021